have joined forces to expand and accelerate the potential benefits of novel cell-based therapies to treat cancer patients
Kiadis is focused on cell-based immunotherapy products for the treatment of life threatening diseases.
Kiadis’ proprietary off-the-shelf NK-cell platform is based on NK-cells from a unique universal donor.
Kiadis has a pipeline of NK-cell based medicines in development to treat blood cancers, solid tumors, and infectious diseases.
Our uncompromising approach to serve patients, their families and care givers aims to minimize harm and maximize help – delivering personalized treatments for every single patient to offer hope, reduce suffering and provide new life.